Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 10/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 6/20 | 0.38 |
| ▸ | GRM5 | P41594 | 3/20 | 0.37 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP1 | P63208 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
| ▸ | KAT7 | O95251 | 1/20 | 0.36 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26185725 | 0.88 | CSNK1E (0.39) | CSNK1ECSNK1DGRM5 | |
| SCHEMBL26185733 | 0.83 | KAT7 (0.34) | GRM5CKS1BSKP1SKP2KAT7 | |
| SCHEMBL24277086 | 0.80 | CSNK1E (0.43) | CSNK1ECSNK1D | |
| SCHEMBL24277111 | 0.80 | CSNK1E (0.41) | CSNK1ECSNK1D | |
| SCHEMBL30461913 | 0.79 | CSNK1E (0.38) | CSNK1ECSNK1DCKS1BSKP1SKP2 | |
| SCHEMBL29308599 | 0.74 | GRM5 (0.44) | CSNK1ECSNK1DGRM5MEN1KMT2A | |
| SCHEMBL31018685 | 0.73 | CKS1B (0.41) | CKS1BSKP1SKP2KDM4EPKM | |
| SCHEMBL24277112 | 0.73 | GRM5 (0.44) | GRM5KAT7KAT8MEN1KMT2A | |
| SCHEMBL24276951 | 0.73 | CSNK1E (0.36) | CSNK1ECSNK1D | |
| SCHEMBL16728571 | 0.71 | CSNK1E (0.62) | CSNK1ECSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595264-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20230331732-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331732-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331732-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-10-19 | — | — | US | disclosed |
| EP-4211139-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2022052958-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022052958-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595264-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, GCGR | CSNK1E 914/4885CSNK1D 527/4885GRM5 1354/4885 |
| US-20230331732-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | CSNK1E 2813/4885CSNK1D 2074/4885GRM5 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.